CELLECTIS - ADR (CLLS) Stock Fundamental Analysis

NASDAQ:CLLS • US15117K1034

3.68 USD
-0.12 (-3.16%)
Last: Mar 3, 2026, 03:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

CLLS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. CLLS has a bad profitability rating. Also its financial health evaluation is rather negative. CLLS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CLLS had negative earnings in the past year.
  • CLLS had a negative operating cash flow in the past year.
  • CLLS had negative earnings in each of the past 5 years.
  • In the past 5 years CLLS reported 4 times negative operating cash flow.
CLLS Yearly Net Income VS EBIT VS OCF VS FCFCLLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -28.25%, CLLS is in the better half of the industry, outperforming 67.69% of the companies in the same industry.
  • With a Return On Equity value of -102.97%, CLLS perfoms like the industry average, outperforming 44.04% of the companies in the same industry.
Industry RankSector Rank
ROA -28.25%
ROE -102.97%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
CLLS Yearly ROA, ROE, ROICCLLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • CLLS has a better Gross Margin (3.66%) than 71.73% of its industry peers.
  • The Profit Margin and Operating Margin are not available for CLLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLLS Yearly Profit, Operating, Gross MarginsCLLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CLLS has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CLLS has more shares outstanding
  • The debt/assets ratio for CLLS has been reduced compared to a year ago.
CLLS Yearly Shares OutstandingCLLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLLS Yearly Total Debt VS Total AssetsCLLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • CLLS has an Altman-Z score of -0.50. This is a bad value and indicates that CLLS is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.50, CLLS is in line with its industry, outperforming 57.31% of the companies in the same industry.
  • A Debt/Equity ratio of 0.91 indicates that CLLS is somewhat dependend on debt financing.
  • The Debt to Equity ratio of CLLS (0.91) is worse than 73.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Altman-Z -0.5
ROIC/WACCN/A
WACC6.65%
CLLS Yearly LT Debt VS Equity VS FCFCLLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.38 indicates that CLLS should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.38, CLLS is doing worse than 82.31% of the companies in the same industry.
  • A Quick Ratio of 1.38 indicates that CLLS should not have too much problems paying its short term obligations.
  • CLLS's Quick ratio of 1.38 is on the low side compared to the rest of the industry. CLLS is outperformed by 81.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.38
CLLS Yearly Current Assets VS Current LiabilitesCLLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • CLLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.80%, which is quite impressive.
  • Looking at the last year, CLLS shows a very strong growth in Revenue. The Revenue has grown by 154.92%.
  • CLLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.44% yearly.
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
Revenue 1Y (TTM)154.92%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.89%

3.2 Future

  • Based on estimates for the next years, CLLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -54.16% on average per year.
  • The Revenue is expected to grow by 25.15% on average over the next years. This is a very strong growth
EPS Next Y-166.15%
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
EPS Next 5YN/A
Revenue Next Year45.52%
Revenue Next 2Y32.52%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLLS Yearly Revenue VS EstimatesCLLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
CLLS Yearly EPS VS EstimatesCLLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CLLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLLS Price Earnings VS Forward Price EarningsCLLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLLS Per share dataCLLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A cheap valuation may be justified as CLLS's earnings are expected to decrease with -54.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CLLS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CELLECTIS - ADR

NASDAQ:CLLS (3/3/2026, 3:16:28 PM)

3.68

-0.12 (-3.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-11
Inst Owners15.56%
Inst Owner Change20.41%
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap369.20M
Revenue(TTM)112.63M
Net Income(TTM)-99.99M
Analysts84.62
Price Target7.62 (107.07%)
Short Float %0.76%
Short Ratio7.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.93%
Min EPS beat(2)4.37%
Max EPS beat(2)25.48%
EPS beat(4)4
Avg EPS beat(4)48.46%
Min EPS beat(4)4.37%
Max EPS beat(4)145.69%
EPS beat(8)7
Avg EPS beat(8)30.86%
EPS beat(12)9
Avg EPS beat(12)22.27%
EPS beat(16)12
Avg EPS beat(16)21.56%
Revenue beat(2)1
Avg Revenue beat(2)21.17%
Min Revenue beat(2)-20.05%
Max Revenue beat(2)62.39%
Revenue beat(4)3
Avg Revenue beat(4)64.94%
Min Revenue beat(4)-20.05%
Max Revenue beat(4)161.56%
Revenue beat(8)5
Avg Revenue beat(8)33.5%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.18%
PT rev (3m)0.36%
EPS NQ rev (1m)-1.47%
EPS NQ rev (3m)-1.47%
EPS NY rev (1m)0%
EPS NY rev (3m)15.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)50.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.95
P/FCF N/A
P/OCF N/A
P/B 3.8
P/tB 3.85
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.93
BVpS0.97
TBVpS0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.25%
ROE -102.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.66%
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.89%
Cap/Sales 3.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.38
Quick Ratio 1.38
Altman-Z -0.5
F-Score3
WACC6.65%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
EPS Next Y-166.15%
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
EPS Next 5YN/A
Revenue 1Y (TTM)154.92%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.89%
Revenue Next Year45.52%
Revenue Next 2Y32.52%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%
EBIT growth 1Y46.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.42%
EBIT Next 3Y-33.24%
EBIT Next 5Y-29.24%
FCF growth 1Y50.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.93%
OCF growth 3YN/A
OCF growth 5YN/A

CELLECTIS - ADR / CLLS FAQ

What is the ChartMill fundamental rating of CELLECTIS - ADR (CLLS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CLLS.


Can you provide the valuation status for CELLECTIS - ADR?

ChartMill assigns a valuation rating of 0 / 10 to CELLECTIS - ADR (CLLS). This can be considered as Overvalued.


How profitable is CELLECTIS - ADR (CLLS) stock?

CELLECTIS - ADR (CLLS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CELLECTIS - ADR?

The Earnings per Share (EPS) of CELLECTIS - ADR (CLLS) is expected to decline by -166.15% in the next year.